The JDRF T1D Fund is a revolutionary venture philanthropy fund that aims to drive cures for type 1 diabetes (T1D) by catalyzing private investment. Established in 2015, the fund was born out of the realization that there was a significant gap between scientific advancements in T1D and the delivery of solutions to those in need due to a lack of private investment. To bridge this gap, the JDRF T1D Fund operates as a separate entity, utilizing its capital and expertise to convince venture capital, biotech, and pharma to invest in T1D.

With $175 million in assets, it has become one of the largest disease-focused venture philanthropy funds globally. The fund's portfolio consists of investments in therapeutics, diagnostics, devices, and vaccines, with a strong focus on cure-oriented therapies. By combining venture capital and philanthropy, the JDRF T1D Fund creates a new investment market dedicated to delivering life-changing solutions for individuals living with or at risk of developing T1D.

As the front door to all T1D commercial opportunities, the fund leverages JDRF's expertise in T1D research, advocacy, and network, ensuring the most promising opportunities are pursued while de-risking investments for private investors. This unique partnership enables the fund to secure the billions needed to ultimately find a cure for T1D